- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
No Wall Street Crash for Biotech
When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday.
When Warren Buffet was ten, he made his first trip to NYC. What did he want to do? “See the Stock Exchange,” he told a news reporter on TV yesterday. “It is the epicenter of Capitalization.” Buffet claims he feels exactly the same excitement today as he did then as a ten year old whenever he visits the Floor. He was in NYC to promote his son Peter’s book, “Life is What You Make It.”
This month, of course, marks the anniversary of The Wall Street Crash of 1929, the most devastating stock market crash in the history of the United States. The crash signaled the beginning of the 10-year Great Depression that affected all Western industrialized countries. We’re holding our breath, but so far it looks like clear sailing with no October surprises in store, especially for biotech.
As of yesterday, the 10 Best Biotech Stocks for 2013 were looking like this. (Source: TheStreet Ratings
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
